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Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM,
and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted
option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its
anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but signiﬁcantly increased.
The immuno-related adverse eﬀects may be severe and life threatening.
1.Introduction
Malignant melanoma (MM) is one of the most diﬃcult
neoplasms to treat. Unlike most common cancers, the last 20
years have seen no real improvement in systemic therapy for
patients with metastatic MM. Currently the median survival
for patients with metastatic MM is commonly limited to 6–9
months [1, 2]. However, some clinical and histopathological
evidence exists providing clear demonstration of the ability
of immunotherapy to mediate regression from the early to
the advanced stages of MM [3–5]. The anti-MM lympho-
cytes consist of CD4+ and CD8+ T cells in part presenting as
tumour-inﬁltrating lymphocytes (TIL). Among them, vari-
ous clones of cytotoxic T lymphocytes (CTLs) are key cells to
as p e c i ﬁ ca n t i - M Mr e s p o n s e[ 6, 7].
The past decade has witnessed much advances in the
understanding of the complexity and redundancy in the
immunological and other biological systems involved in MM
proliferation, invasion, and metastasis [8–11]. A range of
new drugs have been developed to speciﬁcally target the
relevant pathways [12]. A number of immunotherapy trials
for metastatic MM including cytokines, vaccines, adoptive
immunotherapy, and their combinations were conducted in
recent years [13]. A new promising MM therapy is emerging
in the ﬁeld of antibody-based speciﬁc targeting [14, 15].
Attempts were made at targeting either MM cells directly or
immune cells involved in the anti-MM activity.
2.CTLA-4
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) corre-
spondingtoCD152isexpressedatthesurfaceofsomeTcells.
CTLA-4 is a member of the immunoglobulin superfamily
[13–15] acting as a downregulator of the immune system
and playing a key role in the inhibition of the anticancer
immunity [16]. With the exception of CD4+CD25+, Foxp3+
T-regulatory cells (Tregs) resting lymphocytes do not express
CTLA-4.Stimulation ofCTLA-4atthe CTLsurfaceresultsin
inhibition of their proliferation.
The CTLA-4 expressed at the CTLs surface binds to both
B7-1 and B7-2 (CD80 and CD86) ligand pairs present on
antigen-presenting cells. Their interaction activates a cell-
signaling cascade leading to the cell cycle arrest of CTLs
[16]. This mechanism results in T-cell anergy and interferes2 Dermatology Research and Practice
with both IL-2 secretion and IL-2 receptor expression, lead-
ing in turn to inhibition of T-cell priming and immune
escape, thereby allowing neoplastic growth [17]. It produces
immune control by inhibition of T-cell responses contribut-
ing to self-antigen tolerance [18]. By contrast, CD28 binding
to B7-1 and B7-2 leads to stimulation of CTL proliferation
and production of IL-2. Because of its expression on den-
dritic cells, eﬀector T cells, and regulatory T cells, CTLA-4
exhibits multiple roles at various stages of the immune re-
sponse.
Blocking CTLA-4 is thought to shift the balance of the
immune response, enhancing both the recognition of tum-
ourantigensandtheneoplasticregression[17].Consequent-
ly, this process decreases tolerance to self-antigens, leading to
autoimmunity [5, 18]. CTLA-4 blockade causes a dynamic
shift in the ratio between Tregs and CD8+ TCLs culminating
in eﬀective immune recognition of neoplasms [19]. This
event was documented in posttreatment biopsies of neo-
plasms treated with CTLA-4 blockade and correlated with
therapy-mediated tumoral necrosis [20, 21].
3.Tremelimumab
Tremelimumab was a fully human IgG2 anti-CTLA-4 mono-
clonal antibody. Partial response (PR) was initially reported
to reach 6.6% for a period extending 8.9 to 29.8 months
[22, 23]. Despite such early promise, a more recent phase III
trial failed to show a greater survival beneﬁt than traditional
chemotherapy. The drug was subsequently abandoned.
4.Ipilimumab
Ipilimumab (MDX-010: Medarex, Bristol-Myers Squibb) is
a fully humanized IgG1 monoclonal antibody directed to
CTLA-4 [13–15, 19–21, 24–29] .O b j e c t i v er e s p o n s er a t e s
combiningcompleteresponse(CR)andPRwereintherange
of 5–20% [15, 29]. Disease control rates (CR + PR + stable
disease) were reported averaging 15–30%. In contrast, the
two therapies approved by the FDA, high-dose interleukin-
2, and dacarbazine are each associated with response rate of
only 10 to 20% and a small percentage of CR. They are not
thought to improve overall survival (OS) [30].
Studies involving higher doses of ipilimumab were asso-
ciatedwithhigherresponseratesbutwithincreasedtoxicities
[19, 24–26]. Ipilimumab is the ﬁrst therapeutic agent show-
ingprolongedOS(medianOS:10.1months)inpatientswith
metastatic MM. This ﬁgure must be compared to the median
survivalinsuchapatientpopulationwithothercurrentther-
apies generally reaching 6–9 months [1, 2, 28].
Ratesofadversereactionstoipilimumab,particularlyau-
toimmune events, appear to be dose- and schedule-depend-
ent. Toxicities associated with ipilimumab diﬀer from those
typically related to regular cytotoxic chemotherapy [31–33],
and they create unique challenges in diagnosis and clinical
management [34]. The majority of adverse events to ipil-
imumab are immune mediated, corresponding to the so-
called “immune-related adverse events (irAEs)” [35, 36].
The irAEs aﬀect a range of organs, including the skin,
gastrointestinal tract, and endocrine glands. Antinuclear
antibodies (ANA) are not associated with irAEs, and they
have no diagnostic value in this setting, since many patients
with MM show baseline elevations of ANA titers.
The ipilimumab irAEs are dose-dependent, schedule-re-
lated,andcumulative[34]. Grade 3 and 4 irAE were reported
in 20–30% of patients. Close clinical and laboratory mon-
itoring is required for early detection and timely initiation
of treatment with immunosuppressive therapies. Most irAEs
were manageable and generally reversible under corticother-
apy. Long-term residual irAEs requiring treatment were
reported at 2-year followup in phase III trials, primarily cor-
responding to dermatologic eﬀects (rash, vitiligo, and pru-
ritus), colitis/diarrhea, and endocrine-related adverse events
[25]. In addition, life-threatening irAEs (bowel perforation
due to immune colitis) and treatment-related mortality were
reported in about 2% of ipilimumab-treated patients. Addi-
tional immunosuppression was sometimes required [37, 38].
Up to 50% of treatment-related deaths were associated with
irAEs [29].
5. Conclusion
Immunotherapy, particularly blockade of the CTLA-4 path-
way,hasalreadyprovenaneﬀectagainstadvancedMM.Ipili-
mumab is the ﬁrst agent demonstrating promise in the treat-
ment of metastatic MM. The positive but modest OS beneﬁt
requiresmoreinvestigations.Itseemsessentialtotailortreat-
ment options to those patients most likely to beneﬁt, espe-
cially because the treatment is associated with frequent and
sometimes life-threatening irAE. Overall, the inherent risks
of immunotherapy require judicious use in appropriately
selected patients by well-informed clinicians and patients.
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